Tuesday May 22 | Seeking Alpha
Stem Cell Hype Has Yet To Breed Profits
Over the past few years, stem cell therapies have emerged as an intriguing new frontier in biotechnology research as scientists have begun exploring ways to monetize stem cells' unique plasticity.
Geron Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Friday.
Geron Corporation Reports 2012 First Quarter Financial Results and Highlights
Menlo Park, Calif, May 2, 2012 - Geron Corporation today reported financial results for the first quarter ended March 31, 2012.
BioTime: Backed By Dubious Stock Promoters
In our previous article , we discussed how BioTime, Inc. has used press releases, particularly regarding the creation and acquisition of numerous subsidiaries, to boost the company's share price.
Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results
Menlo Park, Calif., April 25, 2012 - Geron Corporation will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, after the close of market.